<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513500</url>
  </required_header>
  <id_info>
    <org_study_id>GHS-A-00-00020-00-5</org_study_id>
    <nct_id>NCT00513500</nct_id>
  </id_info>
  <brief_title>Zambia Integrated Management of Malaria and Pneumonia Study</brief_title>
  <acronym>ZIMMAPS</acronym>
  <official_title>Zambia Integrated Management of Malaria and Pneumonia Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for International Health and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the effectiveness and feasibility of
      community-based management of pneumonia and malaria by community health workers (CHWs) in a
      rural district of Zambia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia and malaria are the two leading causes of morbidity and mortality among children
      under five in sub-Saharan Africa. Due to limited access to health services in many developing
      countries, a number of global health organizations, including the World Health Organization,
      have strongly advocated the use of community health workers (CHWs) to deliver basic health
      care in the community and to facilitate referral to primary health facilities.

      Existing supported CHWs in the study area will be trained in the assessment and
      classification of children between six months and five years of age presenting with fever
      and/or cough/difficult breathing. In the intervention arm, CHWs will be supplied with rapid
      diagnostic tests (RDTs), Coartem (a fixed dose combination of artemether-lumefantrine) and
      amoxicillin. The intervention CHWs will be trained to use RDTs in patients with reported
      fever and provide those with a positive result with Coartem; and patients suspected of
      pneumonia (based on fast breathing) will be treated with amoxicillin as per the standard of
      care at health facilities and monitored. In the control arm, no RDT will be performed. The
      CHWs will be supplied with Coartem to treat malaria/febrile illness as per the integrated
      management of childhood illnesses (IMCI) guidelines and patients suspected of pneumonia will
      be referred to the health facility for treatment as per the current practice. Data collectors
      will routinely visit CHWs to collect data on their consultations and follow-up patients
      treated by CHWs in their homes..
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Children Who Received Early and Appropriate Treatment for Pneumonia.</measure>
    <time_frame>one year</time_frame>
    <description>Early and appropriate is defined as receiving 13-15 doses of amoxicillin over 5 days and receiving the first dose within 24-48 hours of onset of first symptom</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Children Who do Not Respond to Treatment for Pneumonia</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3125</enrollment>
  <condition>Pneumonia</condition>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem and amoxicillin</intervention_name>
    <description>Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
    <description>Give Coartem without RDT and refer fast breathing</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 6 months and 5 years

          -  Present with history of fever or reported fever

          -  Present with cough or difficult breathing

        Exclusion Criteria:

          -  Age below 6 months and above 5 years

          -  Presence of signs and symptoms of severe illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kojo Yeboah-Antwi, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for International Health and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chikankata Health Services</name>
      <address>
        <city>Chikankata</city>
        <state>Southern Province</state>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>April 27, 2010</results_first_submitted>
  <results_first_submitted_qc>June 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2010</results_first_posted>
  <last_update_submitted>July 13, 2010</last_update_submitted>
  <last_update_submitted_qc>July 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kojo Yeboah-Antwi</name_title>
    <organization>Center for International Health and Development</organization>
  </responsible_party>
  <keyword>community health care</keyword>
  <keyword>community health worker</keyword>
  <keyword>malaria</keyword>
  <keyword>pneumonia</keyword>
  <keyword>rapid diagnostic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enhanced Treatment</title>
          <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
        </group>
        <group group_id="P2">
          <title>Current Practice</title>
          <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1017"/>
                <participants group_id="P2" count="2108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="976"/>
                <participants group_id="P2" count="2054"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hospitalized</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enhanced Treatment</title>
          <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
        </group>
        <group group_id="B2">
          <title>Current Practice</title>
          <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1017"/>
            <count group_id="B2" value="2108"/>
            <count group_id="B3" value="3125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1017"/>
                    <measurement group_id="B2" value="2108"/>
                    <measurement group_id="B3" value="3125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="14.0"/>
                    <measurement group_id="B2" value="23.6" spread="14.7"/>
                    <measurement group_id="B3" value="23.3" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="484"/>
                    <measurement group_id="B2" value="1028"/>
                    <measurement group_id="B3" value="1512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                    <measurement group_id="B2" value="1080"/>
                    <measurement group_id="B3" value="1613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Zambia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1017"/>
                    <measurement group_id="B2" value="2108"/>
                    <measurement group_id="B3" value="3125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Children Who Received Early and Appropriate Treatment for Pneumonia.</title>
        <description>Early and appropriate is defined as receiving 13-15 doses of amoxicillin over 5 days and receiving the first dose within 24-48 hours of onset of first symptom</description>
        <time_frame>one year</time_frame>
        <population>The number of participants determined for this analysis was based on those classified as pneumonia. The analysis was based on an intent-to-treat basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Treatment</title>
            <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
          </group>
          <group group_id="O2">
            <title>Current Practice</title>
            <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children Who Received Early and Appropriate Treatment for Pneumonia.</title>
          <description>Early and appropriate is defined as receiving 13-15 doses of amoxicillin over 5 days and receiving the first dose within 24-48 hours of onset of first symptom</description>
          <population>The number of participants determined for this analysis was based on those classified as pneumonia. The analysis was based on an intent-to-treat basis.</population>
          <units>partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>5.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>8.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)</title>
        <time_frame>one year</time_frame>
        <population>The participants analyzed was based on children reported with fever. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Treatment</title>
            <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
          </group>
          <group group_id="O2">
            <title>Current Practice</title>
            <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)</title>
          <population>The participants analyzed was based on children reported with fever. Analysis was per intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
                <count group_id="O2" value="2084"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="2066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children Who do Not Respond to Treatment for Pneumonia</title>
        <time_frame>one year</time_frame>
        <population>Based on number classified as having pneumonia. Analysis was per intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Treatment</title>
            <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
          </group>
          <group group_id="O2">
            <title>Current Practice</title>
            <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children Who do Not Respond to Treatment for Pneumonia</title>
          <population>Based on number classified as having pneumonia. Analysis was per intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Patients were followed up on Day 5-7 and caregivers were specifically asked about adverse events and documented on a case report form.
The participants at risk to RDT related adverse events in the Enhanced Treatment Arm were 973 because RDT was not done on 44 subjects (no fever = 36; refused = 6; and poor light at the time of visit =2).</desc>
      <group_list>
        <group group_id="E1">
          <title>Enhanced Treatment</title>
          <description>Intervention: Treatment for malaria and pneumonia:
Treat malaria based on rapid diagnostic test with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Treat pneumonia with half tablet (250mg amoxicillin) for children weighing 5 - 9.9kg and one tablet (250mg amoxicillin for children weighing 10-20kg three times a day for five days.</description>
        </group>
        <group group_id="E2">
          <title>Current Practice</title>
          <description>Control: Treatment for malaria and pneumonia referral Treat malaria based on fever with half tablet (20mg artemether, 120mg lumefantrine) for children weighing 5-9.9kg and one tablet (20mg artemether, 120mg lumefantrine) for children weighing 10-20kg twice a day for three days.
Refer children with pneumonia to the nearest health facility.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1017"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Deaths</sub_title>
                <counts group_id="E1" events="1017" subjects_affected="2" subjects_at_risk="1017"/>
                <counts group_id="E2" events="2108" subjects_affected="1" subjects_at_risk="2108"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1017" subjects_affected="4" subjects_at_risk="1017"/>
                <counts group_id="E2" events="2108" subjects_affected="14" subjects_at_risk="2108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="973"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RDT related</sub_title>
                <description>These adverse effects with related to pricking the finger to take blood for rapid diagnostic test</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="973"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2018"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Imbalance in enrollment. More patients enrolled in the control arm possibly due to many control community health workers working full time and available to see patients all day.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kojo Yeboah-Antwi</name_or_title>
      <organization>Boston University</organization>
      <phone>617-414-1275</phone>
      <email>kyantwi@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

